Langues Français
Actifs pris en charge
MRNAc logo

Moderna

Avant ouverture

Ouvrir Mo

232,85 $US

-sur la période sélectionnée

+4,41 $US (+1,93 %)depuis la clôture américaine

Prix onchain
-
Prime / décote
-
Mis à jour Référence

Écarts de prix avant frais et coûts d’exécution. Comparer les prix

Analyses

Can Moderna’s melanoma data drive lasting growth beyond COVID vaccines? They weigh cash burn, manufacturing risk and valuation versus oncology upside.

COVID‑19 vaccine revenue sustainability

The conventional assumption is that the COVID-19 vaccine business settles into a seasonal annuity in the $1–2 billion range, analogous to a severe-flu product.

In the current environment it is not, and the difference is worth roughly $1 billion a year to Moderna's revenue line. The company cannot manage this risk with better science, a better formulation or a lower price.

Moderna, Inc. (MRNA) — The Platform and the Price | Farstar CapitalModerna, Inc. (MRNA) — The Platform and the Price | Farstar Capital

Oncology pipeline validation and commercialization

Moderna, Inc. (NASDAQ: MRNA) and Merck & Co., Inc. (NYSE: MRK) said a Phase 3 melanoma trial of intismeran plus Keytruda met its recurrence-free survival and distant metastasis-free survival endpoints. Both companies described the improvements as statistically significant and clinically meaningful.

The melanoma Phase 3 result and influenza approval strengthen the platform and diversification claims, while missing effect-size detail, manufacturing complexity, cash burn and financing keep commercialization and per-share value unresolved. What it did not provide was the underlying data: the hazard ratios, the survival curves, the magnitude and durability of the benefit.

Why Is Moderna, Inc. (NASDAQ: MRNA) Stock Up 569% This Year?Why Is Moderna, Inc. (NASDAQ: MRNA) Stock Up 569% This Year?Moderna Is Up About 500% in 2026. Oct. 24 Could Double It or Erase the Rally. – Investment House

Cash burn and path to breakeven

It holds $6.9 billion of cash, equivalents and investments as at 30 June 2026, and guides to $4.7–5.2 billion at year-end. It has committed to reaching cash breakeven in 2028. That commitment requires revenue to roughly double from the 2026 base while cash operating costs stay inside a guided 2027 range of $3.5–3.9 billion.

The company lost $2.82 billion in 2025 and $2.13 billion in the first half of 2026 alone, of which $900 million was a non-recurring litigation settlement. First-half operating cash use improved to $1.16 billion from $1.96 billion a year earlier, but the first-half net loss was $2.13 billion.

Moderna, Inc. (MRNA) — The Platform and the Price | Farstar CapitalModerna, Inc. (MRNA) — The Platform and the Price | Farstar CapitalWhy Is Moderna, Inc. (NASDAQ: MRNA) Stock Up 569% This Year?

Actualités

Token

Token
MRNAc
Actions par token
1.00000000 MRNA
Contrat
0xb200000000000000000000e215e9b76ecba02468

Obtenir Mo

Conservez-le dans Mo

Conservez MRNAc dans un portefeuille intelligent Mo sur Base que vous contrôlez.

Déplacez-le vite

Envoyez MRNAc à un autre utilisateur Mo sans frais, ou vers tout portefeuille compatible Base de manière quasi instantanée.

Votre argent. Plus de possibilités.